期刊
MULTIPLE SCLEROSIS AND RELATED DISORDERS
卷 10, 期 -, 页码 116-122出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.msard.2016.09.009
关键词
Symbol digit modalities test; Processing speed; Neuropsychological test; Cognition; Changed key; Extended disability status score
资金
- Scleroseforeningen [A-19412]
- Odense University Hospital and Lundbeckfonden (Denmark) [R118-A11472]
- Lundbeck Foundation [R118-2012-11472] Funding Source: researchfish
Objectives: How practice effect influences cognitive testing measured by monthly Symbol Digit Modalities Test (SDMT) during natalizumab treatment, and what factors confound such effect. Methods: Eighty patients were examined monthly with SDMT for 26.22 +/- 8.4 months. After 26.0 +/- 8.1 months, SDMT was also performed with a rearranged key in 59 cases. Results of SDMTs with the rearranged and previous regular key were compared. We examined if gender, age, Extended Disability Status Scale (EDSS), relapses, and disability progression/improvement influence SDMT performed with the regular and the rearranged key, respectively. We also explored if natalizumab applied before regular monthly SDMT may influence practice effect and cognition. Results: SDMT performance improved by 1.2 points/test during the first six months and by 0.4 points/test thereafter. Rearranging the symbols of the key after 26.0 +/- 8.1 months returned SDMT scores to baseline indicating a practice effect. Such practice effect was more significant after longer testing period, but was not influenced by gender, age, relapses, disability progression and prior natalizumab treatment. Although the change from baseline to 2.5 years was significant in subgroups with EDSS 0-3, 3.5-5.5 and 6-7.5, this was higher in patients with EDSS 0-3 compared to 6-7.5. Conclusions: Practice effect significantly contributes to continuous improvement in SDMT performance during natalizumab treatment: to test cognition, a change in key is required. Practice effect is less pronounced in patients with advanced disease. Cognition remains stable even in patients with progressive disease during more than 2 years of natalizumab treatment indicated by scores corresponding to baseline after changing the key.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据